SCHEMBL247706

SCHEMBL247706

CC[C@@H](CO)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10634919 1.00
SCHEMBL40620 1.00
SCHEMBL28920328 0.97
SCHEMBL5160576 0.97
Hydrochloric Acid SCHEMBL27929205 0.97
SCHEMBL5159552 0.97
Water SCHEMBL10355698 0.97
Acetic Acid SCHEMBL5575637 0.95 CA2 (0.50)
Water SCHEMBL5159514 0.95 CA2 (0.50)
Methylene Chloride SCHEMBL8416036 0.92 CA2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11268966-B2 Biomarkers of autism spectrum disorder STEMINA BIOMARKER DISCOVERY, INC. (US) 2022-03-08 US disclosed
EP-3019624-B1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY INC (US) 2020-09-16 EP disclosed
CN-110167944-A Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 利奥制药有限公司 2019-08-23 CN disclosed
CN-110088108-A SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS 利奥制药有限公司 2019-08-02 CN disclosed
US-20190072569-A1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY, INC. 2019-03-07 US disclosed
US-10060932-B2 Biomarkers of autism spectrum disorder STEMINA BIOMARKER DISCOVERY, INC. (US) 2018-08-28 US disclosed
US-20170354713-A1 FGF21 Derivatives and Uses Thereof NOVO NORDISK AS (DK) 2017-12-14 US disclosed
US-20160169915-A1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY, INC. 2016-06-16 US disclosed
EP-3019624-A2 BIOMARKERS OF AUTISM SPECTRUM DISORDER Stemina Biomarker Discovery, Inc. (US) 2016-05-18 EP disclosed
WO-2016021192-A1 PROCESS FOR PRODUCTION OF (S)-(TETRAHYDROFURAN-3-YL)HYDRAZINE EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-02-11 WO disclosed
WO-2011132083-A2 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2011-10-27 WO disclosed
CN-102131773-A Method for producing paricalcitol AZAD PHARMACEUTICAL INGREDIENT 2011-07-20 CN disclosed
EP-2268319-A2 PRECURSORS OF LIPID METABOLISM FOR THE DIAGNOSIS AND TREATMENT OF CANCER Universität Ulm (DE) 2011-01-05 EP disclosed
WO-2009109798-A2 PRECURSORS OF LIPID METABOLISM FOR THE DIAGNOSIS AND TREATMENT OF CANCER UNIVERSITÄT ULM (DE) 2009-09-11 WO disclosed
US-20090203583-A1 Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity NOVACTA BIOSYSTEMS LIMITED (GB) 2009-08-13 US disclosed
CN-101151265-A Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent LG LIFE SCIENCES LTD (KR) 2008-03-26 CN disclosed
EP-1539492-A1 HIGH SPEED NEGATIVE-WORKING THERMAL PRINTING PLATES Kodak Polychrome Graphics, LLC (US) 2005-06-15 EP disclosed
CN-1527830-A Ether derivatives useful as inhibitors of PDE4 isozymes �Ʒ� 2004-09-08 CN disclosed
WO-2004014652-A1 HIGH SPEED NEGATIVE-WORKING THERMAL PRINTING PLATES KODAK POLYCHROME GRAPHICS LLC (US) 2004-02-19 WO disclosed
US-4734367-A OPTICALLY ACTIVE INTERMEDIATES HOFFMANN-LA ROCHE INC. (US) 1988-03-29 US disclosed